Ralph V. Boccia, MD, FACP, explained how community practices can build the workflow and capacity to deliver bispecific step-up dosing in an outpatient setting.
Ralph V. Boccia, MD, FACP, compared MRD data with Tec-Dara and Tal-Dara and explained how sustained MRD negativity is reshaping myeloma care.
The new guidelines include 10 recommendations spanning extended molecular testing, JAK inhibitor use, anemia management, and ...
As radiotherapy becomes more strategically integrated around CAR T-cell therapy in multiple myeloma, clinicians face a choice ...
Erik Bengtsen, MD, shares a key depression screening question and explains when oncologists can start a low-dose ...
In a phase 1 trial of patients with platinum-sensitive high-grade ovarian cancer, a personalized neoantigen vaccine plus ...
Al-Ola A. Abdallah, MD, highlights the data on etentamig, teclistamab/daratumumab, and iberdomide he found most impactful at IMS 2026.
Nikolai Strusberg, MD, discussed how proton therapy and thyroid dose affect clinical hypothyroidism risk after ...
Data from the phase 2/3 QUILT-3.032 trial support the expanded indication for nogapendekin alfa in BCG-unresponsive ...
Boccia, MD, FACP, discussed stopping therapy in patients with deep, sustained responses and the move toward fixed-duration ...
The investigational radiopharmaceutical therapy RYZ101 (225Ac-DOTATATE) produced a statistically significant and clinically ...
Practical guidance for starting belantamab: confirm eligibility, coordinate ophthalmology exams, manage reversible eye ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results